Table 1.

TKIs approved or in phase III testing for use in RCC.

	PFS (months)		Dose	Schedule
	Treatment naive	Cytokine refractory
Pazopanib27	11.1	7.4	800 mg od	Continuous
Sunitinib8,59	11.0	8.3	50 mg od	4 wks on/2 wks off
Sorafenib10,60	5.7	5.5	400 mg bd	Continuous
Axitinib57	NA	12.1	5 mg bd	Continuous
Tivozanib58	14.3	15.8	1.5 mg od	Continuous

Abbreviations: NA, Not available; PFS, Progression Free Survival.